Empiric therapies for Helicobacter pylori infections

CMAJ. Canadian Medical Association Journal

Volumn 183, Issue 9, 2011, Pages

  Graham, David Y ^a   Fischbach, Lori A ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; BISMUTH SALICYLATE; BISMUTH SALT; CLARITHROMYCIN; DOXYCYCLINE; ESOMEPRAZOLE; FURAZOLIDONE; LANSOPRAZOLE; METRONIDAZOLE; NITROIMIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RABEPRAZOLE; RIFABUTIN; TETRACYCLINE; TINIDAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BEDTIME DOSAGE; CLINICAL TRIAL (TOPIC); DRUG CHOICE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; ERADICATION THERAPY; EVENING DOSAGE; HELICOBACTER INFECTION; HUMAN; MORNING DOSAGE; NOTE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POLYPHARMACY; SALVAGE THERAPY; TREATMENT DURATION;

EID: 79958742227     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.101460     Document Type: Note

References (13)

1. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-53.
2. Hunt R, Fallone C. Veldhuyzan van ZS, et al. Canadian Helicobacter Study Group Consensus Conference: Update on the management of Helicobacter pylori - an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H. pylori infection. Can J Gastroenterol 2004;18:547-54. (Pubitemid 39406221)
3. Hunt RH, Smaill FM, Fallone CA, et al. Implications of antibiotic resistance in the management of Helicobacter pylori infection: Canadian Helicobacter Study Group. Can J Gastroenterol 2000; 14:862-8. (Pubitemid 32094295)
4. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007;12:275-8. (Pubitemid 47196342)
5. Hsu PI, Wu DC, Wu JY, et al. Search for a grade A therapy for Helicobacter pylori infection: 14-day sequential or sequential-concomitant hybrid therapy. Gastroenterology 2010;138(Suppl 1):S111.
6. Gisbert JP, Morena F. Systematic review and meta-analysis: levo floxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006;23:35-44. (Pubitemid 43381164)
7. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007;26:343-57. (Pubitemid 47063149)
8. Fischbach LA, van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 2004;20:1071-82. (Pubitemid 39657940)
9. Essa AS, Kramer JR, Graham DY, et al. Meta-analysis: fourdrug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter 2009;14:109-18.
10. Gisbert JP, Calvet X, O'Connor A, et al. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010;44:313-25.
11. Gatta L, Vakil N, Leandro G, et al. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009;104:3069-79.
12. Romano M, Cuomo A, Gravina AG, et al. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial. Gut 2010;59:1465-70.
13. Wu DC, Hsu PI, Wu JY, et al. Sequential and concomitant therapy with 4 drugs are equally effective for eradication of H. pylori infection. Clin Gastroenterol Hepatol 2010;8:36-41.